Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

卡巴拉汀透皮贴剂在痴呆症患者中的实际应用与风险最小化工具的使用

卷 18, 期 4, 2021

发表于: 08 September, 2021

页: [273 - 282] 页: 10

弟呕挨: 10.2174/1567205018666210716120540

open access plus

摘要

背景：透皮贴剂使用方便，特别是在 Rotkreuz ZG Rotkreuz ZG 患有阿尔茨海默病 (AD) 相关性痴呆的患者中。但是，不能忽视补丁管理中各种已识别的错误风险。患者提醒卡（PRC，包括药物记录表 [MRS]）最近被用作风险最小化工具，以防止不正确的贴剂使用 (IU).

目的：本研究旨在评估PRCs 预防IU 的有效性，并调查现实环境中利凡斯的明贴剂的剂量滴定模式。

方法：这项为期 11 个月的多国观察性研究纳入了目前使用利凡斯的明贴剂（4.6 毫克/天、9.5 毫克/天、13.3 毫克/天）的 AD 患者，并由一名护理人员陪同。研究结果是 IU，包括多次贴片使用 (MPU)、贴片放置不正确、其他 IU、PRC 的感知有用性和贴片的滴定模式。

结果：在纳入的 614 名患者中，大多数患者的年龄≥65 岁，并且患有轻度至中度 AD。在研究之前和研究期间，分别有 27.7% 和 18.0% 的患者报告了 IU。大多数患者使用 MRS，73.5% 的患者认为它“有帮助”并且报告的 IU 率低于那些报告“无帮助”的患者（13.9%-16.5% 对 20.2%）。总体而言，141 名患者进行了剂量滴定，平均持续 58 天后，75.8% 的患者从 4.6 毫克/天增加到 9.5 毫克/天。安全性结果与利凡斯的明贴剂的既定概况一致。

结论：PRC 是一种有效的风险最小化工具，可以限制利凡斯的明贴剂的不当使用。大多数需要改变剂量的患者被滴定到 9.5 毫克/天的贴剂。

关键词: 利凡斯的明贴片、不适当的药物使用、多次贴片使用、阿尔茨海默病痴呆、神经退行性疾病、皮质基底膜综合征。

Next »
[1]
Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 2012; 19(9): 1159-79.
[http://dx.doi.org/10.1111/j.1468-1331.2012.03784.x] [PMID: 22891773]
[2]
WHO. The epidemiology and impact of dementia Available from: https://www.who.int/mental_health/neurology/dementia/dementia_thematicbrief_epidemiology.pdf [Accessed on 27th Sep, 2019
[3]
Prince M. World Alzheimer Report 2015 Alzheimer's Disease International Available from: https://www.alz.co.uk/research/worldalzheimerreport2015summary.pdf [Accessed on 18th Dec, 2019
[4]
van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 2005; 76(5): v2-7.
[http://dx.doi.org/10.1136/jnnp.2005.082867] [PMID: 16291918]
[5]
Prizer LP, Zimmerman S. Progressive support for activities of daily living for persons living with dementia. Gerontologist 2018; 58(1): S74-87.
[http://dx.doi.org/10.1093/geront/gnx103]
[6]
Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer’s disease. Int J Alzheimers Dis 2012; 2012: 728983.
[http://dx.doi.org/10.1155/2012/728983] [PMID: 22216416]
[7]
Ngo J, Holroyd-Leduc JM. Systematic review of recent dementia practice guidelines. Age Ageing 2015; 44(1): 25-33.
[http://dx.doi.org/10.1093/ageing/afu143] [PMID: 25341676]
[8]
Bailey JA, Lahiri DK. A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer’s disease. J Neurochem 2010; 112(4): 843-53.
[http://dx.doi.org/10.1111/j.1471-4159.2009.06490.x] [PMID: 19912467]
[9]
Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 2011; 6(7): e21954.
[http://dx.doi.org/10.1371/journal.pone.0021954] [PMID: 21799757]
[10]
Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S. Cholinesterases: Roles in the brain during health and disease. Curr Alzheimer Res 2005; 2(3): 307-18.
[http://dx.doi.org/10.2174/1567205054367838] [PMID: 15974896]
[11]
Characteristics. SoP. Exelon 46 mg/24h transdermal patch 2018. Available from: https://wwwmedicinesorguk/emc/product/1185/smpc#gref.
[12]
Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer’s disease: Focus on rivastigmine. Ther Adv Drug Saf 2018; 9(3): 171-8.
[http://dx.doi.org/10.1177/2042098617750555] [PMID: 29492246]
[13]
Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry 2007; 22(5): 485-91.
[http://dx.doi.org/10.1002/gps.1806] [PMID: 17407176]
[14]
Su J, Liu Y, Liu Y, Ren L. Long-term effectiveness of rivastigmine patch or capsule for mild-to-severe Alzheimer’s disease: A meta-analysis. Expert Rev Neurother 2015; 15(9): 1093-103.
[http://dx.doi.org/10.1586/14737175.2015.1068120] [PMID: 26289489]
[15]
Seibert J, Tracik F, Articus K, Spittler S. Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice. Neuropsychiatr Dis Treat 2012; 8: 141-7.
[PMID: 22536070]
[16]
Ueda K, Katayama S, Arai T, et al. Efficacy, safety, and tolerability of switching from oral cholinesterase inhibitors to rivastigmine transdermal patch with 1-step titration in patients with mild to moderate Alzheimer’s disease: A 24-week, open-label, multicenter study in Japan. Dement Geriatr Cogn Disord Extra 2019; 9(2): 302-18.
[http://dx.doi.org/10.1159/000501364] [PMID: 31572426]
[17]
Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT. Efficacy of rivastigmine transdermal patch on activities of daily living: Item responder analyses. Int J Geriatr Psychiatry 2011; 26(4): 356-63.
[http://dx.doi.org/10.1002/gps.2534] [PMID: 21312297]
[18]
Bernabei R, Rossini PM, Di Cioccio L, et al. Compliance and caregiver satisfaction in alzheimer’s disease: Results from the AXEPT study. Dement Geriatr Cogn Disord Extra 2012; 2(1): 418-32.
[http://dx.doi.org/10.1159/000338228] [PMID: 23139687]
[19]
Heneka N, Shaw T, Rowett D, Lapkin S, Phillips JL. Exploring factors contributing to medication errors with opioids in australian specialist palliative care inpatient services: A multi-incident analysis. J Palliat Med 2018; 21(6): 825-35.
[http://dx.doi.org/10.1089/jpm.2017.0578] [PMID: 29473770]
[20]
Lövborg H, Holmlund M, Hägg S. Medication errors related to transdermal opioid patches: Lessons from a regional incident reporting system. BMC Pharmacol Toxicol 2014; 15: 31.
[http://dx.doi.org/10.1186/2050-6511-15-31] [PMID: 24912424]
[21]
Lampert A, Seiberth J, Haefeli WE, Seidling HM. A systematic review of medication administration errors with transdermal patches. Expert Opin Drug Saf 2014; 13(8): 1101-14.
[http://dx.doi.org/10.1517/14740338.2014.926888] [PMID: 24921682]
[22]
Ali TB, Schleret TR, Reilly BM, Chen WY, Abagyan R. Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada. PLoS One 2015; 10(12): e0144337.
[http://dx.doi.org/10.1371/journal.pone.0144337] [PMID: 26642212]
[23]
Lövborg H, Jönsson AK, Hägg S. A fatal outcome after unintentional overdosing of rivastigmine patches. Curr Drug Saf 2012; 7(1): 30-2.
[http://dx.doi.org/10.2174/157488612800492717] [PMID: 22663954]
[24]
Suzuki Y, Kamijo Y, Yoshizawa T, Fujita Y, Usui K, Kishino T. Acute cholinergic syndrome in a patient with mild Alzheimer’s type dementia who had applied a large number of rivastigmine transdermal patches on her body. Clin Toxicol (Phila) 2017; 55(9): 1008-10.
[http://dx.doi.org/10.1080/15563650.2017.1329536] [PMID: 28594244]
[25]
EMA. Committee for Medicinal Products for Human Use Exelon (rivastigmine). 2013.
[26]
Good Publication Practices of ISPE 2007. Available from: https://ispe.org/publications/guidance-documents [Accessed on 27th Sep, 2019
[27]
Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. Epidemiology 2007; 18(6): 805-35.
[http://dx.doi.org/10.1097/EDE.0b013e3181577511] [PMID: 18049195]
[28]
Niu H, Álvarez-Álvarez I, Guillén-Grima F, Aguinaga-Ontoso I. Prevalence and incidence of Alzheimer’s disease in Europe: A meta-analysis. Neurologia 2017; 32(8): 523-32.
[http://dx.doi.org/10.1016/j.nrl.2016.02.016] [PMID: 27130306]
[29]
Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2015; 9: CD001191.
[PMID: 26393402]

Rights & Permissions Print Cite
Article Metrics
31
2
© 2024 Bentham Science Publishers | Privacy Policy